Pulmonary fibrosis is thought to result from dysregulated wound repair after repetitive lung injury. Many cellular responses to injury involve rearrangements of the actin cytoskeleton mediated by the two isoforms of the Rho-associated coiled-coil-forming protein kinase (ROCK), ROCK1 and ROCK2. In addition, profibrotic mediators such as transforming growth factor-b, thrombin, and lysophosphatidic acid act through receptors that activate ROCK. Inhibition of ROCK activation may be a potent therapeutic strategy for human pulmonary fibrosis. Pharmacological inhibition of ROCK using nonselective ROCK inhibitors has been shown to prevent fibrosis in animal models; however, the specific roles of each ROCK isoform are poorly understood. Furthermore, the pleiotropic effects of this kinase have raised concerns about on-target adverse effects of ROCK inhibition such as hypotension. Selective inhibition of one isoform might be a better-tolerated strategy. In the present study, we used a genetic approach to determine the roles of ROCK1 and ROCK2 in a mouse model of bleomycin-induced pulmonary fibrosis. Using ROCK1-or ROCK2-haploinsufficient mice, we found that reduced expression of either ROCK1 or ROCK2 was sufficient to protect them from bleomycin-induced pulmonary fibrosis. In addition, we found that both isoforms contribute to the profibrotic responses of epithelial cells, endothelial cells, and fibroblasts. Interestingly, ROCK1-and ROCK2-haploinsufficient mice exhibited similar protection from bleomycin-induced vascular leak, myofibroblast differentiation, and fibrosis; however, ROCK1-haploinsufficient mice demonstrated greater attenuation of epithelial cell apoptosis. These findings suggest that selective inhibition of either ROCK isoform has the potential to be an effective therapeutic strategy for pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF) is a devastating disease of progressive respiratory decline associated with high morbidity and mortality and a median time to organ failure and death of only 3 years from the time of diagnosis (1) . In 2014, nintedanib and pirfenidone received Food and Drug Administration approval for patients with IPF after clinical trials demonstrated that each drug slowed the rate of lung function decline (2, 3) . Though this was a critical advance, a great unmet need remains for more effective IPF treatments capable of stopping or even reversing the progression of pulmonary fibrosis. The development of novel therapeutic strategies will require a better understanding of the biological processes that drive pulmonary fibrosis.
Multiple mediators thought to contribute to pulmonary fibrosis, such as lysophosphatidic acid (LPA), thrombin, and transforming growth factor-b (TGF-b), have receptors that activate Rho-associated coiled-coil-forming protein kinase (ROCK) as part of their signaling pathways (4) . ROCK activation in the lungs has been demonstrated in the bleomycin mouse model of pulmonary fibrosis, as well as in the lungs of patients with IPF (5) . There are two human and mouse isoforms of ROCK, ROCK1 and ROCK2 (6) . In mice, inhibition of both ROCK isoforms with nonselective pharmacologic inhibitors, such as fasudil and Y-27632, has been shown to prevent the development of pulmonary fibrosis when administered before bleomycin challenge, as well as to induce regression when administered after fibrosis has already been established (5, (7) (8) (9) . Taken together, these data suggest that ROCK inhibition may be a particularly promising therapeutic strategy for pulmonary fibrosis.
Although inhibition of ROCK has great potential to mitigate pulmonary fibrosis, the pleiotropic effects of this kinase have raised concerns about on-target adverse effects of nonselectively inhibiting both ROCK isoforms together, such as hypotension (10) . It has been reported that at least one ROCK inhibitor, Y-27632, inhibits smooth muscle contraction and corrects the blood pressure in hypertensive rat models (11) .
In the present study, we sought to evaluate the individual contributions of the two ROCK isoforms to pulmonary fibrogenesis to determine whether selective inhibition of either ROCK1 or ROCK2 may provide similar antifibrotic effects while minimizing untoward consequences. The two ROCK isoforms are structurally similar, particularly in their kinase domains, where they are 90% homologous (6) . Both fasudil and Y-27632 target these kinase domains and inhibit ROCK1 and ROCK2 with equal potency (12) . Consequently, the effects of these inhibitors in vivo cannot be attributed to the inhibition of one ROCK isoform versus the other. We therefore took a genetic approach to evaluate ROCK1 and ROCK2 individually. Prior genetic targeting experiments have indicated that ROCK1 and ROCK2 have nonredundant functions in vivo (13, 14) . Homozygous deletion of either ROCK1 or ROCK2 leads to nonviability of most offspring, indicating that the ability of these isoforms to compensate for each other is not complete. Furthermore, the causes of nonviability, as well as the phenotypes of the rare survivors, differ between isoform deletions, which are consistent with these isoforms having nonredundant functions (13, 14) . To investigate the contributions of the individual ROCK isoforms to the development of pulmonary fibrosis in adult mice, we induced fibrosis through injection of intratracheal bleomycin in mice that were haploinsufficient for ROCK1, ROCK2, or both isoforms. Previous investigations have shown that these mice are viable into adulthood, exhibit an approximately 50% reduction in protein expression of each ROCK isoform, and have informative phenotypes in several other disease models (15) (16) (17) .
In this study, we found that haploinsufficiency of either ROCK isoform protects from the development of pulmonary fibrosis in the bleomycin model. Given the pleiotropic effects of ROCK signaling, we evaluated whether ROCK1 and/or ROCK2 haploinsufficiency mitigated several different essential profibrotic responses to bleomycininduced lung injury, involving three different cell types: 1) alveolar epithelial cell apoptosis, 2) loss of endothelial cell barrier function and vascular leak, and 3) myofibroblast differentiation. We found differing contributions of the two ROCK isoforms in these three different profibrotic responses, further indicating that ROCK1 and ROCK2 serve nonredundant functions during the development of pulmonary fibrosis. Our findings demonstrate that even partial inhibition of a single ROCK isoform could have therapeutic efficacy, which is encouraging because we know that some degree of ROCK activity is important for maintaining normal homeostasis.
Methods

Animals
ROCK1-haploinsufficient (ROCK1
1/2
) and ROCK2-haploinsufficient (ROCK2 1/2 ) mice were generated as described previously (16) . Mice haploinsufficient for both isoforms (ROCK1 1/2 2 1/2 mice) were generated by crossing ROCK1
1/2 and ROCK2 1/2 mice. ROCK1 1/2 2 1/2 mice were underrepresented in the litters produced, representing approximately 10% of pups rather than the expected 25%, but these mice appeared to be phenotypically normal. DNA was extracted from tail snips of all mice used in experiments to identify their ROCK1 and ROCK2 genotypes. The control mice used are described in the METHODS section of the data supplement. The mice were maintained in a specific pathogen-free environment certified by the American Association for Accreditation of Laboratory Animal Care. All protocols performed were approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee. For experiments, we used mice at 8-12 weeks of age, and whenever required, mice were anesthetized with ketamine (80 mg/kg) and xylazine (10 mg/kg).
Western Blotting
Whole-lung lysates were separated by SDS-PAGE and then transferred to polyvinylidene difluoride membranes using the NuPAGE electrophoresis and transfer systems (Life Technologies) under reducing conditions. After blocking with 5% milk, membranes were incubated with anti-ROCK1 or anti-ROCK2 primary antibodies (both from BD Transduction Laboratories) followed by horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology), and then they were visualized with Amersham enhanced chemiluminescence substrate (GE
Clinical Relevance
The development of pulmonary fibrosis is thought to be driven by aberrant or overexuberant woundhealing responses to recurrent lung injury, including exaggerated alveolar epithelial cell apoptosis, pulmonary vascular permeability, and fibroblast activation. We demonstrate that both isoforms of Rho-associated coiledcoil-forming protein kinase (ROCK), ROCK1 and ROCK2, contribute to all three of these processes, as well as to the development of pulmonary fibrosis, in the bleomycin model. Partial inhibition of either ROCK isoform or both together thus has the potential to be an effective therapeutic strategy for pulmonary fibrosis. Importantly, complete elimination of both isoforms is not required for an antifibrotic phenotype. Healthcare). Membranes were then stripped and similarly reprobed for GAPDH as a loading control. Densitometry of the immunoblots was performed using ImageJ software (NIH).
Bleomycin-induced Pulmonary Fibrosis
Fibrosis was induced by single-dose intratracheal injection of bleomycin (Fresenius Kabi) at 1.2 U/kg and quantified by measuring hydroxyproline content, as previously described (18) .
Histological Analysis and Immunohistochemistry
Lungs were inflated with 10% formalin at 25 cm H 2 O for 15 minutes after the right ventricle was flushed with PBS. Lungs were subsequently excised and fixed in 10% formalin before being embedded in paraffin. Paraffin-embedded 5-mm sections were stained with hematoxylin and eosin (H&E) or Masson's trichrome stain. For immunohistochemical analyses of epithelial apoptosis and myofibroblast differentiation, TUNEL staining or staining with an anti-a-smooth muscle actin (anti-a-SMA) antibody, respectively, was performed on deparaffinized lung sections as previously described (19, 20) . TUNEL quantification was averaged by blinded counting of 10 highpowered fields per sample. a-SMA immunohistochemistry was quantified as mean expression over each entire slide using WinROOF imaging software (Mitani Shoji Co.).
Assessment of Vascular Permeability
Lung vascular permeability was assessed by measuring BAL albumin concentration using ELISA kits specific for mouse albumin (Bethyl Laboratories) according to the manufacturer's instructions. To measure vascular permeability in vivo, Evans blue (EB) dye assays were performed as described previously (18, 21) .
Human Fibroblast Experiments
Human lung fibroblasts were collected from discarded excess tissue from surgical lung resections. Additional details are provided in the METHODS section of the data supplement.
Statistical Analysis
Differences between groups were analyzed for statistical significance with two-tailed Student's t tests, except for hydroxyproline assays, which were analyzed with one-tailed tests, using Microsoft Excel software (Microsoft). P < 0.05 was considered significant for all comparisons.
Results
Characterization of ROCK1 and ROCK2 Expression in ROCK-Haploinsufficient Mice
We confirmed the genotypes of ROCK1 Figure E1 in the data supplement). There was a small compensatory increase in the alternate isoform in the singlehaploinsufficient mice. ROCK1 expression was significantly increased in ROCK2 ), ROCK2-haploinsufficient (ROCK2 1/2 ), and double-haploinsufficient (ROCK1 1/2 2 1/2 ) mice. (A) The genotype of pups in litters produced by mating ROCK1
1/2 and ROCK2 1/2 mice were distinguished by PCR amplification of tail DNA from each mouse using allele-specific primers. The representative gels demonstrate the PCR products generated from DNA from wild-type (WT), ROCK1 mice had regained weight to slightly above their prechallenge baseline, and all three ROCK-haploinsufficient genotypes were significantly closer to their baseline weights than were WT control mice ( Figure 2C ).
ROCK1 Haploinsufficiency Protects against Bleomycin-induced Alveolar Epithelial Cell Apoptosis to a Greater Extent than ROCK2 Haploinsufficiency
Apoptosis of alveolar epithelial cells (AECs) is a postinjury event observed in IPF lungs and shown to contribute to the development of pulmonary fibrosis in mouse models (22) (23) (24) (25) . ROCK activation has been reported to promote AEC detachment induced by cyclic stretch and hyperoxia, and ROCK1 specifically has been implicated in driving the cellular machinery involved in the execution phase of apoptosis (26, 27) .
We have previously demonstrated that AEC apoptosis peaks early after bleomycin challenge at Days 1 and 3 and then wanes by Day 5 (19 Figure 3A ). Although ROCK1
1/2 and ROCK2 1/2 mice both had significantly fewer apoptotic AECs than WT control mice postbleomycin challenge ( Figure 3B ), protection from AEC apoptosis was significantly greater in ROCK1
1/2 than in ROCK2
mice. ROCK1 1/2 2 1/2 mice also had significantly reduced numbers of apoptotic AECs compared with WT control mice ( Figure 3B ), but this reduction was not significantly different from that seen in mice haploinsufficient for ROCK1 alone. These results indicate that both ROCK1 and ROCK2 contribute to bleomycininduced AEC, but that ROCK1 plays a Increased pulmonary vascular permeability and subsequent leak of profibrotic proteins such as thrombin have been shown to contribute to the development of pulmonary fibrosis by promoting thrombin-dependent a v b 6 integrin-mediated TGF-b activation (28) . Nonselective pharmacologic inhibition of both ROCK isoforms has been shown to protect against vascular leak after lung injury (29) . These results implicate ROCK as a critical mediator of lung injury-induced vascular permeability (29) . To characterize the contributions of both ROCK1 and ROCK2 isoforms to the increase in lung vascular permeability induced by bleomycin, we performed EB dye extravasation assays and measured albumin extravasation from the plasma into the airspaces. To characterize the time course of bleomycin-induced vascular permeability, we assessed BAL albumin concentrations in naive WT mice (Day 0) and in WT mice at Days 3, 7, and 14 postbleomycin challenge ( Figure 4A ). BAL albumin concentrations significantly increased after bleomycin challenge in WT mice, rising progressively from Day 0 to Day 14. We measured hydroxyproline content in the lungs of these same mice at each time point and found that lung collagen was not significantly increased from baseline values until Day 14 postchallenge ( Figure 4B ). We therefore selected Day 7 as the time point at which to evaluate ROCK contributions to vascular permeability, because it represents the time of maximum vascular leak before the establishment of fibrosis in this model. At this time point, we saw significant reductions in BAL albumin concentrations of ROCK1
, and ROCK1 1/2 2 1/2 mice compared with WT control mice, demonstrating that reduction of either isoform was associated with a reduction in lung vascular permeability ( Figure 4C ).
We performed EB dye assays on naive and Day 7 post-bleomycin WT control mice, in addition to ROCK1
1/2 and ROCK2 1/2 mice, to evaluate the contribution of each ROCK isoform to the loss of lung endothelial barrier function in vivo. At Day 7 post-bleomycin challenge, vascular permeability was significantly reduced in the lungs of both ROCK1 1/2
and ROCK2
1/2 mice compared with WT control mice ( Figure 4D ). EB dye indices, calculated as the ratio of lung to plasma dye concentrations ([EB] lung/[EB] plasma), were significantly reduced in both ROCK1
1/2 and ROCK2 1/2 mice compared with WT control mice ( Figure 4E ). These results indicate that both ROCK1 and ROCK2 contribute to vascular permeability induced by bleomycin lung injury.
Both ROCK1 and ROCK2 Contribute to Bleomycin-induced Fibroblast Differentiation to Myofibroblasts
In Vivo ROCK activation in fibroblasts has previously been shown to be required for their differentiation into myofibroblasts in response to either biochemical stimuli such as TGF-b or biomechanical stimuli such as increased stiffness of the extracellular matrix (ECM) (30) (31) (32) . To investigate the role of ROCK isoforms in the activation of myofibroblasts in the bleomycin-induced pulmonary fibrosis model, we performed immunofluorescence ( Figure 5A , left panels) and immunohistochemical ( Figure 5A , right panels) staining on lung sections from mice of all experimental groups at Day 14 post-bleomycin with an antibody that recognizes a-SMA, a marker of myofibroblast differentiation. a-SMA is expressed at baseline in smooth muscle cells that line both blood vessels and airways in the lungs. We performed immunohistochemical staining of lung sections from WT control mice in addition to ROCK1 Figure 5B ).
In Vitro Either ROCK Isoform Is Sufficient for Human Lung Fibroblastto-Myofibroblast Differentiation in Response to TGF-b
We performed in vitro experiments inducing myofibroblast differentiation of normal human lung fibroblasts in response to TGF-b after knocking down expression of either isoform ROCK1 or ROCK2 or both using siRNA transfection. ROCK1 and ROCK2 mRNA expression were each reduced by 80% with siRNA transfection compared with nontargeting control siRNA ( Figures 6A and 6B ). Although we did not observe a significant decrease in a-SMA expression with individual ROCK1 or ROCK2 knockdown as compared with nontargeting siRNA in response to TGF-b, we found that siRNA knockdown of both ROCK1 and ROCK2 simultaneously was required to reduce a-SMA expression in response to TGF-b ( Figure 6C ). We did observe a significant reduction in collagen expression with ROCK1 knockdown or with knockdown of both isoforms in response to TGF-b ( Figure 6D ).
Discussion
We have shown that each of the two ROCK isoforms, ROCK1 and ROCK2, contributes to the development of pulmonary fibrosis in the bleomycin mouse model, as well as that reduction in each isoform is protective against bleomycin-induced pulmonary fibrosis. Our use of mice that were genetically haploinsufficient for ROCK1 or ROCK2 allowed us to evaluate the contributions of each of these isoforms individually. Despite their kinase domains being 90% homologous, we found that only a 50% reduction of either ROCK1 or ROCK2 was sufficient to significantly protect mice from bleomycin-induced pulmonary fibrosis, as well as that ROCK1 and ROCK2 are unable to compensate for each other's haploinsufficiency in this model of lung fibrosis.
We also examined whether both ROCK isoforms contribute to several key profibrotic responses to lung injury that are induced by bleomycin challenge: AEC apoptosis, vascular permeability, and myofibroblast differentiation. We found that although both ROCK isoforms contribute to bleomycin-induced AEC apoptosis, ROCK1 made a greater contribution to this profibrotic response to bleomycin injury, as indicated by a greater reduction in AEC apoptosis post-bleomycin challenge in ROCK1-haploinsufficient than in ROCK2-haploinsufficient mice. In contrast, we found that both ROCK isoforms contribute to bleomycin-induced vascular permeability without significant differences between ROCK1
1/2 and ROCK2 1/2 mice. We also demonstrated a similar reduction in a-SMA expression in , and ROCK2 1/2 mice 7 days post-bleomycin challenge and 3 hours post-Evans blue dye injection. (E) Evans blue dye (EB) indices of WT, ROCK1 1/2 , and ROCK2 1/2 mice before and 7 days after bleomycin challenge. Lung and plasma samples were collected from three naive mice/group and three WT, four ROCK1 1/2 , and four ROCK2 1/2 mice at Day 7 post-bleomycin challenge. Experiments with naive and bleomycin-challenged mice were performed separately. The experiment with bleomycin-challenged mice was repeated twice, and data shown are from one experiment that was representative of results in both. Data are expressed as mean 6 SEM EB index. *P , 0.05 compared with WT mice at D7.
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fibroblasts in vivo at Day 14 after bleomycin in both ROCK1-and ROCK2-haploinsufficient mice; in vitro, however, we saw a reduction in a-SMA only with siRNA knockdown of both ROCK1 and ROCK2 together. We thus found differing contributions of the two ROCK isoforms for the different profibrotic responses to lung injury that we investigated, further indicating that ROCK1 and ROCK2 serve nonredundant functions during the development of pulmonary fibrosis.
In the prevailing paradigm of IPF pathogenesis, fibrosis results from aberrant wound-healing responses to repetitive injury that primarily targets AECs (33) . In response, AECs undergo apoptosis at an increased rate. Increased AEC apoptosis is sufficient by itself to drive pulmonary fibrosis in mouse models when it is induced by anti-Fas antibody (23), overexpression of TGF-b (24), or diphtheria toxin-induced injury targeted directly to AECs (25) . Patients with IPF have been observed to have increased numbers of apoptotic AECs as well (22) .
Both ROCK1 and ROCK2 are downstream mediators of cell surface receptors such as LPA 1 . We previously demonstrated that LPA signaling through LPA 1 also contributes to the development of AEC apoptosis after bleomycin challenge: LPA 1 -deficient mice also had reduced numbers of apoptotic AECs at 1 and 3 days post-bleomycin challenge compared with WT mice (19) . We found evidence that LPA-LPA 1 signaling mediates lung epithelial cell anoikis, the apoptosis of anchorage-dependent cells induced by their detachment. We found that LPA specifically induced lung epithelial cell detachment but did not influence the rate at which cells became apoptotic once they were detached. ROCK activation has been shown to promote AEC detachment induced by injurious stimuli other than bleomycin challenge. Exposure of AECs to cyclic stretch and hyperoxia induced their detachment, which was prevented by pharmacologic ROCK inhibition with the non-isoform-selective inhibitor Y-27632 (26) . ROCK1 more than ROCK2 may therefore promote AEC apoptosis after bleomycin challenge by inducing AEC detachment and anoikis, a hypothesis we will explore in future studies. In addition to promoting AEC apoptosis by promoting cell detachment, ROCK1 specifically has also been implicated in driving the cellular machinery involved in the execution phase of apoptosis (27) . ROCK1 but not ROCK2 is cleaved to a truncated active form by caspases during apoptosis. This constitutively active form of ROCK1 promotes the actin-myosin contractility that drives the characteristic membrane bleb formation of the final stages of apoptosis. In addition to AEC apoptosis, ROCK1 and/or ROCK2 promote other profibrotic activities of AECs after lung injury. Activation of the prototypical profibrotic cytokine TGF-b after lung injury is initially dependent on activation of the epithelial cell-restricted integrin a n b 6 , which occurs through a ROCK-dependent pathway (34) . AECs are also responsible for the production of other cytokines that activate fibroblasts after lung injury, including connective tissue growth factor (CTGF) (35) . AEC production of CTGF is dramatically suppressed by pharmacologic ROCK inhibition with the non-isoform-selective inhibitor Y-27632 (36) . Determining which ROCK isoform(s) mediate these other profibrotic AEC activities will be the subject of our future studies.
Exaggerated pulmonary vascular permeability is also one of the aberrant wound-healing responses to repetitive lung injury that can contribute to the development of pulmonary fibrosis. Increased vascular permeability is one of the cardinal responses to tissue injury in general (37), and we have previously shown that increased vascular leak after lung injury promotes the development of pulmonary fibrosis in the bleomycin mouse model (21) . In patients with IPF, lung vascular permeability is increased and predicts outcome. Clearance rates of an inhaled radiolabeled macromolecule, 99m Tcdiethylenetriaminepentaacetic acid, were faster in patients with IPF than in control subjects, and among patients with IPF, faster clearance rates were associated with more rapid declines in pulmonary function and increased mortality (38, 39) . Similarly, BAL/plasma protein ratios were elevated in patients with IPF compared with control subjects, and they were greatest in those patients who died within 3 years of follow-up (40) .
Endothelial barrier function is maintained by adherens and tight junctions between adjacent endothelial cells that mediate cell-cell adhesion. ROCK activation within endothelial cells promotes actin-myosin contractility, which provides the physical force that pulls adjacent cell membranes apart from one another, opening paracellular gaps through which plasma and plasma proteins leak into the airspaces (41) . Paracellular gap formation induced by multiple edemagenic mediators, including thrombin, LPA, vascular endothelial growth factor, and TNF-a, has been shown to be suppressed by pharmacologic ROCK inhibition and consequently to be ROCK dependent (29, (42) (43) (44) (45) (46) . We found that pulmonary vascular leak induced in the bleomycin model of lung fibrosis was markedly reduced in mice that were haploinsufficient for ROCK1 or ROCK2, suggesting that activation of both ROCK isoforms is required to promote the endothelial cell actin-myosin contractility that drives paracellular gap formation and vascular leak after lung injury.
Exaggerated fibroblast recruitment and fibroblast differentiation into myofibroblasts are also among the aberrant wound-healing responses to repetitive lung injury that contribute to the development of pulmonary fibrosis. Fibroblast activation and differentiation into myofibroblasts are responsible for ECM production and contraction in pulmonary fibrosis. Fibroblast differentiation into myofibroblasts can be directed by biochemical stimuli, such as TGF-b, and/or by biomechanical stimuli, such as increased stiffness of the ECM. ROCK activation in fibroblasts has previously been shown to be required for their differentiation into myofibroblasts in response to either class of stimulus: ROCK inhibition suppresses myofibroblast differentiation induced by TGF-b (30, 31) and myofibroblast differentiation induced by increased matrix stiffness (32) . ROCK inhibition has also been shown to suppress fibroblast migration (7), indicating that this profibrotic fibroblast function is ROCK dependent as well. We found that myofibroblast accumulation induced in the lung in the bleomycin model was markedly reduced in mice that were haploinsufficient for ROCK1 or ROCK2, suggesting that activation of both ROCK isoforms is required to promote myofibroblast accumulation.
In vitro reduction of a-SMA was only significant with knockdown of both isoforms. This finding matches the results of another recent publication in which researchers reported that loss of a-SMA fiber assembly was seen on stiff matrix only in the absence of both ROCK isoforms (47) . The interesting difference we found between in vivo and in vitro a-SMA expression in activated fibroblasts could be due to several variables. In our haploinsufficient mouse model, there is reduction in ROCK expression in all cell types, so the ultimate effect on myofibroblast differentiation could be due to reduction in ROCK in more than just fibroblasts. In vivo there are also additional mediators other than TGF-b present, so although our in vitro data suggest that single-isoform reduction is insufficient to block TGF-b-induced myofibroblast differentiation, it may be sufficient to block differentiation induced by other mediators, and this could be explored in future studies.
Our findings that mice that were haploinsufficient for either ROCK1 or ROCK2 were protected from bleomycininduced pulmonary fibrosis, as well as from bleomycin-induced AEC apoptosis, vascular leak, and myofibroblast differentiation, suggest that specifically targeting one ROCK isoform could be an effective therapeutic strategy for pulmonary fibrosis. Whether there is increased benefit from reduction of both ROCK isoforms is unclear on the basis of our current data. Other than underrepresentation in litters, we did not observe adverse effects of a genetic reduction in both isoforms. Reductions in bleomycin-induced increases in apoptotic AECs observed in WT mice were greater in ROCK1-haploinsufficient mice, although the differences between ROCK1-and ROCK2-haploinsufficient mice with respect to quantification of fibrosis by lung hydroxyproline did not reach statistical significance. ROCK signaling is centrally involved in the vascular smooth muscle cell contraction that regulates blood pressure (48) , and its inhibition consequently may precipitate hypotension (10) . It has been reported that at least one ROCK inhibitor, Y-27632, inhibits smooth muscle contraction and corrects the blood pressure in hypertensive rat models (11) . Expression and activity of ROCK2 is higher than ROCK1 in vascular smooth muscle cells (49) , suggesting that ROCK2 may be more involved in regulation of systemic blood pressure than ROCK1 and that ROCK2 inhibition may be more likely to induce hypotension than ROCK1 inhibition. The nonselective ROCK inhibitor fasudil has been used in Japan to treat cerebral vasospasm after intracerebral hemorrhage. Although postmarketing studies did not show high rates of hypotension with this treatment (50), fasudil is a relatively weak ROCK inhibitor, and concerns about hypotension remain for the possible development of more potent ROCK inhibitors for the treatment of pulmonary fibrosis. Therefore, our results do support consideration of selective inhibition of ROCK1 as a targeting strategy that both maximizes antifibrotic efficacy and minimizes potential unwanted on-target effects.
One potential limitation in our data is that in the ROCK2-haploinsufficient mice, there was a statistically significant upregulation of ROCK1 (seen by Western blotting in Figure 1 ). This could suggest that reduction of overall ROCK activity is not reduced as much as it is in the ROCK1-haploinsufficient mice.
In summary, our study provides evidence derived from specific genetargeting experiments that ROCK is critically involved in the development of pulmonary fibrosis, consistent with the results of prior studies using pharmacologic ROCK inhibitors. Our results build on these previous studies by demonstrating that both ROCK isoforms, ROCK1 and ROCK2, contribute to multiple profibrotic responses to lung injury, including AEC apoptosis, vascular leak, and myofibroblast differentiation. Why both isoforms are so important for these processes will be the subject of future mechanistic studies. Our results suggest that selective targeting of individual ROCK isoforms may have some benefit as a therapeutic strategy for pulmonary fibrosis without additional evidence for mitigation of unwanted on-target adverse effects. We believe that inhibition of ROCK has great potential as an antifibrotic therapy based on its significant roles in many key fibrotic mechanisms. Partial reduction of ROCK activity, perhaps even normalization of the increased activity reported in IPF, has the potential to be an effective therapeutic strategy for pulmonary fibrosis because it permits the remaining ROCK activity to participate in nonfibrotic functions necessary for homeostasis. n Author disclosures are available with the text of this article at www.atsjournals.org.
